ERBB2 and neoplasm: Luminal B tumours, on the other hand, show a more complex genomic pattern with additional amplifications in 8p11 (FGFR1 locus), 8q21, 11q13, 17q12 (HER2 locus) and 20q13, associated with therapy resistance, an increased risk of relapse and poor prognosis [3, 20–24].